https://orcid.org/0000-0002-2600-4021
References
- DO Monte Lameiro TM, Denadai R, Pereira-Filho JC, et al. Treatment of facial infantile hemangioma: comparative study between propranolol and ethanolamine oleate. J Craniofac Surg. 2018;29(6):1514–1517.
- Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360.
- Fu Y, Yang ZG, Zhao LY. Angiogenesis characteristics of infantile hemangioma and feasibility observation of transplantation model of human hemangioma on mice. Eur Rev Med Pharmacol Sci. 2017;21(6):1276–1280.
- Aletaha M, Salour H, Bagheri A, et al. Oral propranolol for treatment of pediatric capillary hemangiomas. J Ophthal Vis Res. 2012;6(2):130–137.
- Xu G, Lv R, Zhao Z, et al. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad Dermatol. 2012;67(6):1210–1213.
- Léauté-Labrèze C, De La Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–2651.
- Mashiah J, Kutz A, Rabia SH, et al. Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. Int J Dermatol. 2017;56(2):148–153.
- Ran Y, Chen S, Dai Y, et al. Successful treatment of oral itraconazole for infantile hemangiomas: a case series. J Dermatol. 2015;42(2):202–206.
- Head SA, Shi W, Zhao L, et al. Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc Natl Acad Sci USA.. 2015;112(52):E7276–E728.
- Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used anti-fungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–399.
- Dang Y, Ren YR, Liu JO. Cholesterol trafficking is required for mTOR activation in endothelial cells. Proc Natl Acad Sci. 2010;107(10):4764–4769.
- Nacev BA, Grassi P, Dell A, et al. The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem. 2011;286(51):44045–44056.
- Goktas S, Sakarya R, Erdogan E, et al. Antiangiogenic effect of itraconazole on corneal neovascularization: a pilot experimental investigation. Ophthalmic Res. 2014;52(4):170–174.
- Chen S, Zhuang K, Sun K, et al. Itraconazole induces regression of infantile hemangioma via down-regulation of the PDGF-D/PI3K/Akt/mTOR pathway. J Investig Dermatol. 2019;139(7):1574–1582.
- Wu HW, Wang X, Zhang L, et al. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Front Oncol. 2018;8:605.
- De Doncker P, Pande S, Richarz U, et al. Itraconazole: what clinicians should know? Indian J Drugs Dermatol. 2017;3:4–10.
- Marqueling AL, Oza V, Frieden IJ, et al. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30(2):182–191.
- Castaneda S, Garcia E, De la Cruz H, et al. Therapeutic effect of propranolol in Mexican patients with infantile hemangioma. Drugs Real World Outcomes. 2016;3(1):25–31.
- Sirachainan N, Lekanan W, Thammagasorn Y, et al. Response to propranolol in infantile hemangioma. Pediatr Internat. 2016;58(7):662–665.
- Panditray S, Acharya S, Prusty N, et al. Management of head and neck hemangiomas in adults: oral propranolol versus oral itraconazole in conjugation with injection sodium tetra decyl sulphate. Indian J Otolaryngol Head Neck Surg. 2018;71(Suppl 1):566–573.
- Zhang L, Wu HW, Yuan W, et al. Propranolol therapy for infantile hemangioma: our experience. DDDT. 2017;11:1401–1408.
- Perry BN, Govindarajan B, Bhandarkar SS, et al. Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Investig Dermatol. 2006;126(10):2316–2322.